Catégorie : Approches sociologiques de la consommation de Cannabis

Alessandro Stella, Publications, 2019

Alessandro Stella Directeur de recherche CNRS Equipe(s) : GEI Laboratoire(s) de rattachement : CRH Coordonnées professionnelles EHESS-CRH GEI (Bureau A 04-11) 54, boulevard Raspail 75006 Paris alessandro.stella (a) wanadoo.fr 01 49 54 24 42 http://gei.ehess.fr/index.php?942  Diplômes 1987 : Diplôme de l’EHESS, sous la direction de Mme Christiane Klapisch-Zuber : « Sur les traces laissées par les Ciompi en révolte : les hommes, les lieux, le travail », rapporteur M. Jacques Le Goff. Prix du meilleur diplôme de l’EHESS. 1992 : Doctorat de l’EHESS, sous la direction de Mme Christiane Klapisch-Zuber : « Un tableau florentin du Trecento. Fiscalité, topographie et société dans la deuxième moitié du XIVe siècle ». Mention : « Très honorable ». 2007 : Habilitation à Diriger des Recherches, Université [...]

Lire la suite

States Want Pot to Grow Greener as Legal Cannabis Expands, Bloomberg Environment, July 19, 2019,

States Want Pot to Grow Greener as Legal Cannabis Expands Bloomberg Environment, Posted July 19, 2019, 12:01 PM https://news.bloombergenvironment.com/environment-and-energy/states-want-pot-to-grow-greener-as-legal-cannabis-expands Sustainability considered as part of legalization Regulations address pesticides, air quality As more states legalize recreational and medical marijuana, they’re confronting the reality that cannabis production involves using huge amounts of pesticides, energy, and water, while generating tons of plant and packaging waste. The result is a patchwork of air, water, pesticide, and waste regulations for the industry across dozens of states, even as the substance remains illegal at the federal level. States like Michigan, where the Marijuana Regulatory Agency will begin accepting business licenses in [...]

Lire la suite

Chanvre industriel, bien-être, cannabis médical, récréatif : pourquoi ces distinctions ?, Aurélien Bernard, NEWSWEED, Cannabis en France, 18 juillet 2019

Chanvre industriel, bien-être, cannabis médical, récréatif : pourquoi ces distinctions ? Aurélien Bernard NEWSWEED, Cannabis en France 18 juillet 2019 Une question nous est revenue à plusieurs reprises suite au récapitulatif du colloque sur le chanvre bien-être : pourquoi parler de « chanvre bien-être » ? Si l’on peut effectivement s’interroger sur la nécessité d’avoir toutes ces dénominations, elles servent pourtant à dissocier à la fois les usages et l’aspect réglementaire franco-français du cannabis. Nous avons donc : du chanvre industriel : variétés de cannabis à -0,2% de THC, pour un usage fibres et graines du chanvre bien-être : variétés de cannabis à -0,2% de [...]

Lire la suite

Le cannabis à visée thérapeutique : travaux du CSST et de l’ANSM. Projet de cadre de la phase expérimentale, RESPADD, Nathalie Richard, juin 2019

Le cannabis à visée thérapeutique : travaux du CSST et de l’ANSM Projet de cadre de la phase expérimentale Direction des médicaments de neurologie-psychiatrie-antalgie-stupéfiants Nathalie Richard Respadd 21 juin 2019   Le cannabis à visée thérapeutique : travaux du CSST et de l’ANSM Nathalie Richard Directrice adjointe ANSM Nathalie RICHARD rappelle que toutes les opérations qui concernent le cannabis sont interdites en France – la production, la détention, l’acquisition et l’utilisation. Des dérogations sont cependant possibles. La première dérogation est liée à une utilisation du cannabis à des fins de recherches. Ainsi, les essais thérapeutiques avec le cannabis possibles en France, sur dérogation du Directeur Général de l’ANSM. L’utilisation de [...]

Lire la suite

The origins of cannabis smoking : Chemical residue evidence from the first millennium BCE in the Pamirs, Meng Ren et al., 2019

The origins of cannabis smoking : Chemical residue evidence from the first millennium BCE in the Pamirs Meng Ren, Zihua Tang, Xinhua Wu, Robert Spengler, Hongen Jiang, Yimin Yang, Nicole Boivin Science Advances, 2019, 5 : eaaw1391 (12 June 2019) DOI: 10.1126/sciadv.aaw1391   Cannabis is one of the oldest cultivated plants in East Asia, grown for grain and fiber as well as for recreational, medical, and ritual purposes. It is one of the most widely used psychoactive drugs in the world today, but little is known about its early psychoactive use or when plants under cultivation evolved the phenotypical trait of increased specialized compound production. [...]

Lire la suite

Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005–2017, Joseph J. Palamar & Austin Le, 2019

Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005–2017 Joseph J. Palamar & Austin Le Human Psychopharmacology Clinical and Experimental, 2019, e2690 DOI: 10.1002/hup.2690   Abstract Objectives : This study aims to examine patterns and first mentions of reported use of new or uncommon drugs across 13 years, among nationally representative samples in the United States. Methods : Participants (ages ≥12) in the National Surveys on Drug Use and Health (2005–2017, N = 730,418) were provided opportunities to type in names of new or uncommon drugs they had ever used that were not specifically queried. We examined self‐reported [...]

Lire la suite

Menace or medicine? Anthropological perspectives on the self-administration of high potency cannabis in the UK, Anna Waldstein, 2010

Menace or medicine? Anthropological perspectives on the self-administration of high potency cannabis in the UK Anna Waldstein Drugs and Alcohol Today • Volume 10 Issue 3 • September 2010   Abstract Domestically produced, high potency cannabis (often referred to as ‘skunk’ in the mainstream UK media) has become increasingly widespread in the UK. This paper considers whether the trend reflects an increased awareness of and desire for medical marijuana. Determining whether cannabis is a drug or a medicine depends on its objective physiological effects – which may vary from one individual to another – as well as how and why those effects are experienced. The [...]

Lire la suite

A burning problem : cannabis lessons learned from Colorado, Jamie E. Parnes et al., 2018

A burning problem: cannabis lessons learned from Colorado Jamie E. Parnes, Adrian J. Bravo, Bradley T. Conner and Matthew R. Pearson ADDICTION RESEARCH & THEORY, 2018, VOL. 26, NO. 1, 3–10 http://dx.doi.org/10.1080/16066359.2017.1315410   ABSTRACT With recent increases in cannabis’ popularity, including being legalized in several states, new issues have emerged related to use. Increases in the number of users, new products, and home growing all present distinct concerns. In the present review, we explored various cannabis-related concerns (i.e. use, acquiring, growing, and public health/policy) that have arisen in Colorado in order to provide information on emerging issues and future directions to mitigate negative outcomes that could [...]

Lire la suite

Modern History of Medical Cannabis : From Widespread Use to Prohibitionism and Back, Simona Pisanti and Maurizio Bifulco, 2017

Modern History of Medical Cannabis : From Widespread Use to Prohibitionism and Back Simona Pisanti and Maurizio Bifulco Trends in Pharmacological Sciences, Cell Press,  2017, 38, 3, 195-198. doi: 10.1016/j.tips.2016.12.002.   Over the history of pharmacology there are numerous examples of drugs being widely distributed, almost ‘trendy’, prescribed by physicians in a certain period as a sort of panacea, and then neglected, forgotten, or even forbidden as they become considered dangerous in the light of clinical observations. One of these drugs is Cannabis, which was very popular in the 19th century until disappearing from the official Pharmacopoeia at the beginning of the 20th century and [...]

Lire la suite

The Need for Federal Regulation of Marijuana Marketing, John W. Ayers et al., 2019

The Need for Federal Regulation of Marijuana Marketing John W. Ayers, PhD, Theodore Caputi, Eric C. Leas, PhD,MPH JAMA, June 11, 2019 Volume 321, Number 22 doi:10.1001/jama.2019.4432   A national for-profit marijuana industry is expanding substantially in the United States. Thirty-three states have legalized medical marijuana, 10 of which (where 1 in 4 individuals reside) have also legalized recreational marijuana. Sales of marijuana are projected to increase from $8.5 billion to $75 billion by 2030, rivaling current tobacco sales ($125 billion).1 The initial marijuana marketplace was limited to a few states, but emerging brands have developed sophisticated national marketing campaigns that could potentially have an [...]

Lire la suite